Meloxicam vs. diclofenac in rheumatology Review article
Article Sidebar
Published:
Dec 31, 2023
Keywords:
osteoarthritis, non-steroidal anti-inflammatory drugs, NSAIDs, rheumatoid arthritis, spondyloarthropathies, ankylosing spondylitis
Main Article Content
Abstract
Nonsteroidal anti-inflammatory drugs used in rheumatic diseases are intended to reduce the intensity of pain and inflammatory response. The patient must take them chronically, so the selected preparation should be not only effective, but also safe. Currently, non-selective drugs and preferential COX-2 inhibitors are used in practice. In this study, on the example of diclofenac (non-selective drug) and meloxicam (COX-2 inhibitor), the anti-inflammatory and analgesic effectiveness of both groups was compared.
Article Details
How to Cite
Sikorska-Siudek, K. (2023). Meloxicam vs. diclofenac in rheumatology. Medycyna Faktow (J EBM), 16(4(61), 372-375. https://doi.org/10.24292/01.MF.0423.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Chen YF, Jobanputra P, Barton P et al. Cyclooxygenase-2 selective non-steroidal antiinflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib, lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008; 12: 1-278.
2. Dequeker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998; 37: 946-51.
3. Kang DO, An H, Park G et al. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. J Am Coll Cardiol. 2020; 76: 518-29.
4. Yocum D, Fleschmann R, Dalgin P et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med. 2000; 160(19): 2947-54.
5. Efstathiou M, Settas L. The effect of non-steroidal anti-inflammatory drugs on matrix metalloproteinases levels in patients with osteoarthritis. Mediter J Rheumatol. 2017; 28(3): 133-41.
6. Ding Ch. Do NSAIDs affect the progression of osteoarthritis? Inflammation. 2002; 26(3): 139-42.
7. Rui-long X, Xia-hao L, Xian-tong K. Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety. Di Yi Jun Yi Da Xue Xue Bao. 2003; 23(5): 460-2.
8. Auvinet B, Ziller R, Appelboom T et al. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients in acute sciatica. Clin Ther. 1995; 17(6): 1078-90.
9. Combe B, Vélicitat P, Garzón N et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001; 50: 10-6.
10. Huskisson EC, Gholzan R, Kurthen R et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis Br J Rheumatol. 1996; (35 suppl 1): 29-34.
11. Furst DE, Kolba KS, Fleischmann R et al. For The Meloxicam Rheumatoid Arthritis Investigators. Dose Response and Safety Study of Meloxicam Up to 22.5 mg Daily in Rheumatoid Arthritis: A 12 Week Multicenter, Double Blind, Dose Response Study versus Placebo and Diclofenac. J Rheumatol. 2002; 29: 436-46.
12. Sonsupap C, Pokhakul P, Kariya T et al. Characteristics of adverse drug reactions due to nonsteroidal anti-inflammatory drugs: a cross-sectional study. Nagoya J Med Sci. 2023; 85: 668-81.
13. Prieto A, De Barrio M, Martín E et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance J Allergy Clin Immunol. 2007; 119(4): 960-4.
14. Bavbek S, Dursun AB, Dursun E et al. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study Int Arch Allergy Immunol. 2007; 142(1): 64-9.
15. CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. Opokan-forte.
16. Euller-Ziegler L, Vélicitat P, Bluhmki E et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res. 2001; 50: 5-9.
2. Dequeker J, Hawkey C, Kahan A et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998; 37: 946-51.
3. Kang DO, An H, Park G et al. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. J Am Coll Cardiol. 2020; 76: 518-29.
4. Yocum D, Fleschmann R, Dalgin P et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med. 2000; 160(19): 2947-54.
5. Efstathiou M, Settas L. The effect of non-steroidal anti-inflammatory drugs on matrix metalloproteinases levels in patients with osteoarthritis. Mediter J Rheumatol. 2017; 28(3): 133-41.
6. Ding Ch. Do NSAIDs affect the progression of osteoarthritis? Inflammation. 2002; 26(3): 139-42.
7. Rui-long X, Xia-hao L, Xian-tong K. Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety. Di Yi Jun Yi Da Xue Xue Bao. 2003; 23(5): 460-2.
8. Auvinet B, Ziller R, Appelboom T et al. Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients in acute sciatica. Clin Ther. 1995; 17(6): 1078-90.
9. Combe B, Vélicitat P, Garzón N et al. Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients. Inflamm Res. 2001; 50: 10-6.
10. Huskisson EC, Gholzan R, Kurthen R et al. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis Br J Rheumatol. 1996; (35 suppl 1): 29-34.
11. Furst DE, Kolba KS, Fleischmann R et al. For The Meloxicam Rheumatoid Arthritis Investigators. Dose Response and Safety Study of Meloxicam Up to 22.5 mg Daily in Rheumatoid Arthritis: A 12 Week Multicenter, Double Blind, Dose Response Study versus Placebo and Diclofenac. J Rheumatol. 2002; 29: 436-46.
12. Sonsupap C, Pokhakul P, Kariya T et al. Characteristics of adverse drug reactions due to nonsteroidal anti-inflammatory drugs: a cross-sectional study. Nagoya J Med Sci. 2023; 85: 668-81.
13. Prieto A, De Barrio M, Martín E et al. Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance J Allergy Clin Immunol. 2007; 119(4): 960-4.
14. Bavbek S, Dursun AB, Dursun E et al. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps. A challenge-proven study Int Arch Allergy Immunol. 2007; 142(1): 64-9.
15. CHARAKTERYSTYKA PRODUKTU LECZNICZEGO. Opokan-forte.
16. Euller-Ziegler L, Vélicitat P, Bluhmki E et al. Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration. Inflamm Res. 2001; 50: 5-9.